Jochen Keupp1, Anne H. Schmieder2, Samuel A. Wickline2, Gregory M. Lanza2, Shelton D. Caruthers2
1Philips Research Europe, Hamburg, Germany; 2C-TRAIN, Washington University, St. Louis, MO, United States
Patient stratification using molecular MRI of angiogenesis could change standard of care in anti-angiogenic therapy. Previously, α ν β 3-integrin targeted nanoparticles (NP) have been shown to detect and quantify angiogenesis in small-animal tumor models based on 19F-MRI. These promising results using Perfluoro-Crown-Ether labels are currently translated to more clinically-relevant Perfluoro-Octyl-Bromide (PFOB) NP. The complex spectral properties of PFOB and the sensitivity to the target-binding process, as observed in this work, require a thorough optimization of imaging parameters on target. In vitro optimization on fibrin clots and in vivo detection of angiogenesis-targeted NP in the vasculature of Vx2-tumor bearing rabbits by 19F-MRI is demonstrated.